ReviewEuropean endocrinology2017

Dipeptidyl Peptidase-4 Inhibitor Development and Post-authorisation Programme for Vildagliptin - Clinical Evidence for Optimised Management of Chronic Diseases Beyond Type 2 Diabetes.

William David Strain et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.